The clinical utility of bone marker measurements in osteoporosis

Journal of Translational Medicine

Jacob M van Laar²  Harish K Datta¹  Stephen P Tuck²  Mohsen Elshahaly²  Gillian Wheater¹ 

[1] Institute of Cellular Medicine, Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne NE1 7RU, UK;Department of Rheumatology, The James Cook University Hospital, Middlesbrough TS4 3BW, UK

关键词: Biological variability;    Osteoporosis;    Bone resorption;    Bone formation;    Bone turnover markers;   

Others  :  826754
DOI  :  10.1186/1479-5876-11-201

 received in 2013-02-11, accepted in 2013-08-21,  发布年份 2013

【 摘 要 】

Osteoporosis is characterised by low bone mass and structural deterioration of bone tissue, resulting in increased fragility and susceptibility to fracture. Osteoporotic fractures are a significant cause of morbidity and mortality. Direct medical costs from such fractures in the UK are currently estimated at over two billion pounds per year, resulting in a substantial healthcare burden that is expected to rise exponentially due to increasing life expectancy. Currently bone mineral density is the WHO standard for diagnosis of osteoporosis, but poor sensitivity means that potential fractures will be missed if it is used alone. During the past decade considerable progress has been made in the identification and characterisation of specific biomarkers to aid the management of metabolic bone disease. Technological developments have greatly enhanced assay performance producing reliable, rapid, non-invasive cost effective assays with improved sensitivity and specificity. We now have a greater understanding of the need to regulate pre-analytical sample collection to minimise the effects of biological variation. However, bone turnover markers (BTMs) still have limited clinical utility. It is not routinely recommended to use BTMs to select those at risk of fractures, but baseline measurements of resorption markers are useful before commencement of anti-resorptive treatment and can be checked 3–6 months later to monitor response and adherence to treatment. Similarly, formation markers can be used to monitor bone forming agents. BTMs may also be useful when monitoring patients during treatment holidays and aid in the decision as to when therapy should be recommenced. Recent recommendations by the Bone Marker Standards Working Group propose to standardise research and include a specific marker of bone resorption (CTX) and bone formation (P1NP) in all future studies. It is hoped that improved research in turn will lead to optimised markers for the clinical management of osteoporosis and other bone diseases.

【 授权许可】

   
2013 Wheater et al.; licensee BioMed Central Ltd.

【 图 表 】

Fig. 3.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Datta HK, Ng FW, Walker JA, Tuck SP, Varanasi SS: The cell biology of bone metabolism-a review. J Clin Path 2008, 61:577-587.
• [2]Carey JJ, Licata AA, Delaney MF: Biochemical markers of bone turnover. Clin Rev Bone Miner Metab 2006, 4(3):197-212.
• [3]Vega D, Maalouf NM, Sakhaee K: The role of receptor activator of nuclear factor-κB (RANK)/RANK Ligand/Osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007, 92(12):4514-4521.
• [4]Leibbrandt A, Penninger JM: RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008, 1143:123-150.
• [5]Klein-Nulend J, Bakker AD, Bacabac RG, Vatsa A, Weinbaum S: Mechanosensation and transduction in osteocytes. Bone 2013, 54(2):182-190.
• [6]Kobayashi Y, Maeda K, Takahashi N: Roles of Wnt signalling in bone formation and resorption. Jpn Dent Sci Rev 2008, 44:76-82.
• [7]Bellido T, Saini V, Pajevic PD: Effects of PTH on osteocyte function. Bone 2013, 54(2):250-257.
• [8]National osteoporosis society. http://www.nos.org.uk/page.aspx?pid=328 webcite
• [9]Tuck SP, Francis RM: Osteoporosis. Postgrad Med J 2002, 78:526-532.
• [10]Bongartz TA, Scholmerich J, Straub RH: From Osteoporosis in postmenopausal women. In Bone disease in rheumatology. Edited by Maricic M, Gluck OS. Arizona: Lippincott Williams and Wilkens; 2005:155-156.
• [11]Bauer D, Garnero P, Harison SL, Cauley JA, Eastell R, Ensrud KE, Orwoll E: Biochemical markers on bone turnover, hip loss and fracture in older men: the MrOS study. J Bone Miner Res 2009, 24(12):2032-2038.
• [12]Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N: A reference standard for the description of osteoporosis. Bone 2008, 42:467-475.
• [13]Rabinda V, Bruyère O, Reginster JY: Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression. Osteoporos Int 2011, 22:893-901.
• [14]Seibel MJ: Biochemical markers of bone turnover: part 1: biochemistry and variability. Clin Biochem Rev 2005, 26:97-122.
• [15]Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-Wauchope A, Douville P, Hanley DA, Jamal SA, Josse R, Kaiser S, Krahn J, Krause R, Kremer R, Lepage R, Letendre E, Morin S, Ooi DS, Papaioaonnou A, Ste-Marie L-G: Bone turnover markers in the management of osteoporosis. Clin Biochem 2009, 42:929-942.
• [16]Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R: Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002, 30(6):886-890.
• [17]Swaminathan R: Biochemical markers of bone turnover. Clin Chim Acta 2001, 313:95-105.
• [18]Qvist P, Munk M, Hoyle N, Christiansen C: Serum and plasma fragments of C-telopeptides of type I collagen (CTX) are stable during storage at low temperatures for 3 years. Clin Chim Acta 2004, 350(1–2):167-173.
• [19]Hannon R, Eastell R: Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 2000, 11(Suppl 6):S30-44.
• [20]Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, for the IOF-IFCC Bone Marker Standards Working Group: Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22:391-420.
• [21]Stokes FJ, Ivanov P, Bailey LM, Fraser WD: The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 2011, 57(1):138-140.
• [22]Blumsohn A, Hannon RA, Eastell R: Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin Chem 1995, 41:318-319.
• [23]Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000, 15(7):1337-1345.
• [24]Marin L, Koivula M-K, Jukkola-Vuorinen A, Leino A, Risteli J: Comparison of total and intact aminoterminal propeptide of type 1 procollagen assays in patients with breast cancer with or without bone metastases. Ann Clin Biochem 2011, 48:447-451.
• [25]Bjarnason NH, Henriksen EEG, Alexandersen P, Christgau S, Henriksen DB, Christiansen C: Mechanism of circadian variation in bone resorption. Bone 2002, 30:307-313.
• [26]Bergmann P, Body JJ, Boonen S, Boutsen Y, Devogelaer JP, Goemaere S, Kaufman JM, Reginster JY, Gangji V, Members of the Advisory Board on Bone Markers: Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian bone club. Int J Clin Pract 2009, 63(1):19-26.
• [27]Wichers M, Schmidt E, Bidlingmaier F, Klingmüller D: Diurnal rhythm of cross laps in human serum. Clin Chem 1999, 45:1858-1860.
• [28]Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD: Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000, 15:1526-1536.
• [29]Rogers RS, Dawson AW, Wang Z, Thyfault JP, Hinton PS: Acute response of plasma markers of bone turnover to a single bout of resistance training or plyometrics. J Appl Physiol 2011, 111:1353-1360.
• [30]Bowsher RR, Sailstad JM: Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: Bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand. J Pharm Biomed Anal 2008, 48(5):1282-1289.
• [31]Kearns AE, Khosla S, Kostenuik PJ: Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodelling in health and disease. Endocr Rev 2008, 29(2):155-192.
• [32]Nicholls JJ, Brassill MJ, Williams GR, Duncan Bassett JH: The skeletal consequences of thyrotoxicosis. J Endocrinol 2012, 213(3):209-221.
• [33]Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S: Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 2010, 95(11):5056-5062.
• [34]Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE: Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010, 95(5):2248-2253.
• [35]Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R: Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 2012, 97(5):1737-1744.
• [36]Garcia-Martin A, Rozas-Moreno P, Reyes-Garcia R, Morales-Santana S, Garcia-Fontana B, Garcia-salcedo JA, Muñoz-Torres M: Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97(1):234-241.
• [37]Melkko J, Hellevik T, Risteli L, Risteli J, Smedsrød S: Clearance of NH2-terminal propeptides of types I and III Procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994, 179:405-412.
• [38]Brandt J, Krogh TN, Jensen CH, Frederiksen JK, Teisner B: Thermal instability of the trimeric structure of the N-terminal propeptide of human Procollagen type I in relation to assay technology. Clin Chem 1999, 45(1):47-53.
• [39]Baxter I, Rogers A, Eastell R, Peel N: Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporos Int 2013, 24:941-947.
• [40]Jabbar S, Drury J, Fordham JN, Datta HK, Francis RM, Tuck SP: Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol 2011, 64:354-357.
• [41]Liu JM, Zhao HY, Ning G, Zhao YJ, Chen Y, Zhang Z, Sun LH, Xu M-Y, Chen JL: Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Int 2005, 76(1):1-6.
• [42]Noble BS: The osteocyte lineage. Arch Biochem Biophys 2008, 473(2):106-11.
• [43]Bonewald LF: Osteocytes: a proposed multifunctional bone cell. J Musculoskelet Neuronal Interact 2002, 2(3):239-41.
• [44]Zhang Y, Wang Y, Li X, Zhang J, Mao J, Li Z, Zhang J, Li L, Harris S, Wu D: The LRP5 high-bone-mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol 2004, 24(11):4677-4684.
• [45]Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D: Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signalling. J Biol Chem 2005, 280:19883-19887.
• [46]You L, Temiyasathit S, Lee P, Kim CH, Tummala P, Yao W, Kingery W, Malone AM, Kwon RY, Jacobs CR: Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone 2008, 42(1):172-179.
• [47]Gross TS, King KA, Rabaia NA, Pathare P, Srinivasan S: Upregulation of osteopontin by osteocytes deprived of mechanical loading or oxygen. J Bone Miner Res 2005, 20(2):250-256.
• [48]Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, Reave J, Skerry TM, Lanyon LE: Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol 2003, 284:C934-C943.
• [49]Amrein K, Amrein S, Drexler C, Dimai HP, Dobnig H, Pfeifer K, Tomaschitz A, Pieber TR, Fahrleitner-Pammer A: Sclerostin and its association with physical activity, age, gender, body composition and bone mineral content in healthy adults. J Clin Endocrinol Metab 2012, 97(1):148-154.
• [50]Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L: Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-Catenin signalling. J Bone Miner Res 2009, 24(10):1651-1661.
• [51]Morse LR, Sudhakar S, Lazzari AA, Tun C, Garshick E, Zafonte R, Battaglino RA: Sclerostin: a candidate biomarker of SCI-induced osteoporosis. Osteoporos Int 2013, 24:961-968.
• [52]Arasu A, Cawthon PM, Lui L-Y, Do TP, Arora PS, Cauley JA, Ensrud KE, Cummings SR: Serum sclerostin and risk of hip fracture in older Caucasian women. J Clin Endocrinol Metab 2012, 97(6):2027-2032.
• [53]Mirza FS, Padhi ID, Raisz LG, Lorenzo JA: Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010, 95(4):1991-1997.
• [54]Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E: Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women – the six-month effect of risedronate and teriparatide. Osteoporos Int 2012, 23:1171-1176.
• [55]McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R: Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 2011, 96(7):E1159-E1162.
• [56]Blumsohn A, Naylor KE, Timm W, Eagleton AC, Hannon RA, Eastell R: Absence of marked seasonal change in bone turnover: a longitudinal and multicentre cross-sectional study. J Bone Miner Res 2003, 18:1274-1281.
• [57]Woitge HW, Scheidt-Nave C, Kissling C, Leidig-Bruckner G, Meyer K, Grauer A, Scharla SH, Ziegler R, Seibel MJ: Seasonal variation of biochemical indices of bone turnover: results of a population-based study. J Clin Endocrinol Metab 1998, 83:68-75.
• [58]Nielsen HK, Brixen K, Bouillon R, Mosekilde L: Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J Clin Endocrinol Metab 1990, 70:1431-1437.
• [59]Chiu KM, Ju J, Mayes D, Bacchetti P, Weitz S, Arnaud CD: Changes in bone resorption during the menstrual cycle. J Bone Miner Res 1999, 14(4):609-615.
• [60]Black AJ, Topping J, Durham B, Farquharson RG, Fraser WD: A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res 2000, 15(3):557-563.
• [61]Dorota D-K, Bogdan KG, Mieczyslaw G, Bozena L-G, Jan O: The concentrations of markers of bone turnover in normal pregnancy and pre-eclampsia. Hypertens Pregnancy 2012, 31:166-176.
• [62]Naylor KE, Iqbal P, Fledelius C, Fraser RB, Eastell R: The effect of pregnancy on bone density and turnover. J Bone Miner Res 2000, 15:129-137.
• [63]Hannon R, Blumsohn A, Naylor K, Eastell R: Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998, 13(7):1124-33.
• [64]van Staa TP, Leufkens HG, Cooper C: The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002, 13:777-787.
• [65]Schett G: Osteoimmunology in rheumatic diseases. Arthritis Res Ther 2009, 11(1):210. BioMed Central Full Text
• [66]Wheater G, Hogan VE, Teng YKO, Tekstra J, Tuck SP, Lafeber FP, Huizinga TWJ, Bijlsma JWJ, Francis RM, Datta HK, van Laar JM: Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos Int 2011, 12:3067-3072.
• [67]Yamaguchi T, Sugimoto T: Bone metabolism and fracture risk in type 2 diabetes mellitus. Endocr J 2011, 58(8):613-624.
• [68]Inque M, Tanaka H, Moriwake T, Oka M, Sekiguchi C, Seino Y: Altered biochemical markers of bone turnover in humans during 120 days of bed rest. Bone 2000, 26(3):281-286.
• [69]Veitch SW, Findlay SC, Hamer AJ, Blumsohn A, Eastell R, Ingle BM: Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporos Int 2006, 17:364-372.
• [70]Vesper H, Cosman F, Endres DB, Garnero P, Hoyle NR, Kleerekoper MK, Mallinak NJS: Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases; approved guideline. NCCLS document 2004, 24(22):1-37.
• [71]Garnero P, Vergnaud P, Hoyle N: Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008, 54(1):188-196.
• [72]Chubb SAP: Measurement of C-terminal telopeptide of type I collagen (CTX) in serum. Clin Biochem 2012, 45(12):928-935.
• [73]Mora S, Pitukcheewanont P, Kaufman FR, Nelson JC, Gilsanz V: Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999, 14:1664-1671.
• [74]Eastell R, Garnero P, Audebert C, Cahall DL: Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. Bone 2012, 50(5):1141-1147.
• [75]Bieglmayer C, Kudlacek S: The bone marker plot: an innovative method to assess bone turnover in women. Eur J Clin Invest 2009, 39:230-238.
• [76]Seibel MJ, Lang M, Geilenkeuser W-J: Interlaboratory variation of biochemical markers of bone turnover. Clin Chem 2001, 47(8):1443-1450.
• [77]Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC: Laboratory reproducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 2010, 21:439-445.
• [78]Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, Myers G, Silverman S, Vesper HW, Lee D, Payette M, Randall S: National bone health alliance bone turnover marker project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int 2012, 23:2425-2433.
• [79]Lee J, Vasikaran S: Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med 2012, 32:105-112.
• [80]Steiger P, Cummings SR, Black DM, Spencer NE, Genant HK: Age related decrements in bone mineral density in women over 65. J Bone Miner Res 1992, 7:625-632.
• [81]Ross PD, Knowlton W: Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998, 13(2):297-302.
• [82]Crane M, Davis T, Kaldale R, Black C, Davies R, Devas V, Williams W: Relating increases in bone mineral density and fracture risk reduction with early suppression in biomarkers of bone turnover: a literature-based meta-analysis of bisphosphonates treatments. J Bone Miner Res 2005, 20(Suppl 1):S95.
• [83]Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J: The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000, 11(Suppl 6):S2-S17.
• [84]Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA: Fracture incidence and association with bone mineral density in elderly men and women: The rotterdam study. Bone 2004, 34:195-202.
• [85]Osteoporosis: assessing the risk of fragility fracture: NICE Clinical Guideline 146 (August 2012). http://www.nice.org.uk/nicemedia/live/13857/60399/60399.pdf webcite
• [86]Blank RD, Malone DG, Christian RC, Vallarta-Ast NL, Krueger DC, Drezner MK, Binkley NC, Hansen KE: Patient variables impact lumbar spine dual energy x-ray absorptiometry precision. Osteoporos Int 2006, 17:768-774.
• [87]The international society for clinical densitometry official position 2007. http://www.iscd.org/official-positions/4th-iscd-position-development-conference-adult/ webcite
• [88]Jordan N, Barry M, Murphy E: Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clin Interv Aging 2006, 1(4):377-387.
• [89]Watts NB, Diab DL: Long-term use of bispohosphonates in osteoporosis. J Clin Endocrinol Metab 2010, 95(4):1555-1565.
• [90]Finkelstein JS, Wyland JJ, Lee H, Neer RM: Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010, 95(4):1838-1845.
• [91]Meier C, Seibel MJ, Kraenzlin ME: From Biochemical markers of bone turnover – clinical aspects. In Contemporary Endocrinology: Osteoporosis: Pathophysiology and Clinical Management Edited by Adler RA. 2010, 131-155. Humana Press